| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.0573 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.0573 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.0573 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.0573 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.1041 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.1488 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.1922 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.1939 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.2051 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.2106 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.2184 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.2326 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.2504 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.2612 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.2622 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.2623 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.2705 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.2708 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.2710 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.2753 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.2771 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.2824 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.2901 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.2934 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.3153 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.3167 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.3276 | scaled units | Placebo | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.3394 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.3413 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.3461 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.3525 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.3546 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.3806 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.3808 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.4072 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.4089 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.4129 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.4134 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.4136 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.4143 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.4579 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.4803 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.4983 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.5343 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.5351 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.5457 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.5518 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.5684 | scaled units | Placebo | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.5737 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.5832 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.5983 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.6226 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.6234 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.6236 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.6335 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.6339 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.6523 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.6599 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.6804 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.6907 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.7082 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.7129 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.7181 | scaled units | Placebo | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.7275 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.7276 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.7691 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.7697 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.7775 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.7801 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.7810 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.7822 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.7993 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.8141 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.8191 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.8204 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.8238 | scaled units | Placebo | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.8292 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.8345 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.8421 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.8461 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.8482 | scaled units | Placebo | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.8494 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.8601 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.8813 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.8817 | scaled units | Placebo | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.8849 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.8867 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.9036 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.9161 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.9501 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.9543 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.9590 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.9710 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 0.9998 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.0000 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.0000 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.0202 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.0290 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.0332 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.0386 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.0577 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.0851 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.0886 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.1063 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.1111 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.1209 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.1311 | scaled units | Placebo | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.1402 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.1642 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.1851 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.1851 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.1963 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.1966 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.1971 | scaled units | Placebo | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.2065 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.2268 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.2638 | scaled units | Placebo | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.2760 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.2786 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.2938 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.3002 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.3039 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.3121 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.3146 | scaled units | Placebo | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.3323 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.3369 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.3417 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.3569 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.3648 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.3702 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.3745 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.3829 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.3884 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.3941 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.4031 | scaled units | Placebo | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.4049 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.4199 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.4295 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.4416 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.4523 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.4609 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.4700 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.4867 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.4909 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.5078 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.5121 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.5143 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.5193 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.5332 | scaled units | Placebo | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.5611 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.5668 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.5806 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.5986 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.6022 | scaled units | Placebo | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.6049 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.6068 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.6120 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.6231 | scaled units | Placebo | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.6280 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.6547 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.6778 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.6987 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.7344 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.7406 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.7576 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.7636 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.7842 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.8181 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.8329 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.8515 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.9038 | scaled units | Placebo | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.9406 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.9408 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.9517 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.9524 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.9604 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 1.9706 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 2.0104 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 2.3437 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 2.7038 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 2.9830 | scaled units | Placebo | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 3.0303 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 3.0330 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 3.1925 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | dihydroorotate | 3.7714 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | dihydroorotate | 3.8104 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | dihydroorotate | 4.1748 | scaled units | Placebo | +47HR POST INFUSION |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|